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[57] ABSTRACT 
A method of testing serum from swine vaccinated 
against pseudorabies virus with viral envelope-based 
subunit vaccines to determine the presence of antibodies 
to infecting pseudorabies virus in wihch an immunoas 
say is performed on the swine serum using a pseudora— 
bies virus antigen preparation comprising nucleocapsid 
proteins of the pseudorabies virus. The universal diag 
nostic antigen is one or more nucleocapsid proteins 
having relative molecular weights of approximately 23 
k. 34 k, 41 k, 63 k and 140 k. 
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METHOD OF DETECTING PSEUDORABIES 
"IRUS SPECIFIC SERUM ANTIBODY BY USE OF 
A UNIVERSAL DIAGNOSTIC ANTIGEN 
GRANT REFERENCE 
The research work leading to this invention was 
funded in part under USDA-ARS Cooperative Agree 
ment Number 58-6125-6-4 and USDA-SEA Special 
Grant No. 83-CRSR-2-2267. 
FIELD OF INVENTION, BACKGROUND AND 
PRIOR ART 
The ?eld of this invention relates to a method of using 
a universal diagnostic antigen derived from pseudora 
bies (PR) virus or prepared by recombinant DNA tech 
niques. More speci?cally, the invention relates to the 
use of non-enveloped structural proteins or nucleocap 
sid proteins as diagnostic antigens, which are comple 
mentary to the antigen of a PR enveloped subunit de 
rived vaccine, thereby permitting PR virus carriers to 
be distinguished from vaccinated swine. For conve 
nience of reference, the abbreviation “PR" is used 
herein to mean “pseudorabies38 . 
Swine found positive in the standard assay procedure 
for the presence of serum antibodies to PR virus, such 
as the enzyme-linked immunosorbant assay (ELISA) 
are assumed to be actual or potential carriers of the 
virus. However, positive reactions may be due to recov 
cry from natural infection and/or vaccine immunization 
or a combination of both, and the swine may not be 
carriers of the virus. Consequently, positive reactions 
for pigs may or may not indicate a carrier of the virus. 
False negative reactions are possible. However, nega 
tive pigs are considered non-carriers with the under 
standing that false negatives do occur occasionally. 
Subunit vaccines for pseudorabies have been devel 
oped and they are prepared to contain less than the full 
complement of antigens from the virus and, speci?cally. 
only the glycoprotein antigens of the virus. US. Pat. 
Nos. 4,470,967 and 4,493,825 describe subunit vaccines 
for PR containing glycoprotein antigens. Subunit vac 
cines consisting of one or more viral enveloped glyco 
proteins should reduce losses due to clinical disease and 
reduce the spread of virus within and between swine 
herds. Further, subunit vaccinated pigs unlike pigs vac 
cinated with traditional vaccines can be certi?ed free of 
PR by testing for antibody to viral components that are 
not part of a subunit vaccine. It is the ability to identify 
virus infected subunit vaccinated pigs that make the 
subunit vaccine useful in control programs. 
Since not all subunit vaccines will consist of the same 
viral glycoprotein, veterinary diagnostic laboratories 
need to have access to accurate vaccination records of 
individual animals and also to have the capacity to test 
for antibodies to several different diagnostic antigens. 
These requirements will increase the cost of control 
programs but can be avoided with the use of a universal 
diagnostic antigen. Pseudorabies virus non'enveloped 
structural proteins or, more speci?cally, nucleocapsid 
proteins are logical candidates for a universal diagnostic 
antigen because they have not been shown to play a role 
in protective immunity and will most likely not be a 
component of subunit vaccines. 
SUMMARY OF THE INVENTION 
For purposes of clari?cation, terms should be de 
?ned. Enveloped proteins are de?ned as structural and 
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nonstructural proteins that are part of the viral enve 
lope. Non-enveloped proteins are de?ned as structural 
and non-structural proteins not associated with the viral 
envelope. Non-enveloped structural proteins are de 
?ned as structural proteins ofthe nucleocapsid. Nucleo 
capsid proteins are de?ned as non-structural and struc 
tural proteins that are associated with the nucleocapsid. 
The non-enveloped structural proteins or, more spe 
ci?cally, the nucleocapsid proteins used in the method 
of this invention can be detected by SDS-PAGE analy 
sis. The Western immunoblot assay is similar to SDS 
PAGE and is used for detecting antibodies to the nu 
cleocapsid proteins. Molecular weights for the nucleo 
capsid proteins can be determined by the method de 
scribed in Stevely, J. Viral, Vol., 16, No. 5, p. 944-950 
(October, 1975). The method involves the measurement 
of molecular weights of the viral proteins calculated 
from their migration on acrylamide gels relative to that 
of standard proteins. The molecular weight or relative 
molecular mass M,, is the ratio of the mass of a molecule 
to one-twelfth of the mass of carbon 12. 
According to the present invention, ?ve nucleocapsid 
proteins have been identi?ed that can be used to detect 
virus infection in pigs vaccinated with viral envelope 
based subunit vaccines. These ?ve nucleocapsid prote 
ins have molecular weights of 140k, 63k, 41k. 34k and 
23k. Combinations of these may also be used to provide 
reliable detection of nucleocapsid speci?c antibody 
response. These proteins are useful as universal diagnos 
tic antigens in direct and competitive enzyme-linked 
immunosorbant assays. 
DESCRIPTION OF THE DRAWINGS 
FIG. 1 describes the relative mobility (RF) of molec 
ular weight standards which are used to construct a 
standard curve by best ?t line/linear regression analysis. 
DETAILED DESCRIPTION 
The present invention relates to a method of testing 
serum from swine vaccinated against pseudorabies virus 
with viral envelope-based subunit vaccines to determine 
the presence of antibodies to infecting pseudorabies 
virus in which an immunoassay is performed on the 
swine serum using a pseudorabies virus antigen prepara 
tion comprising non-enveloped proteins of the pseudo 
rabies virus, specifically, the nucleocapsid proteins. 
The nucleocapsid proteins, i.e., diagnostic universal 
antigens, used in the method of this invention can be 
produced and isolated using a modi?cation of the 
method described by Gibson and Roizman (J. Virol., 
1044-1052, 1972) for the isolation of herpes simplex 
type I and II nucleocapsids. 
For example, a standard roller bottle apparatus may 
be used. A cell line is selected, such as kidney cells 
adapted for in vitro propagation, the cells being ones in 
which PR virus replicates freely. The cells are intro 
duced into the roller bottles together with a suitable cell 
growth medium. Virus infected cells are harvested 24 
hours later with the aid of glass beads and pelleted by 
low speed centrifugation. The cell pellets are washed 
three times in 500 mM NaCl, 20 mM Tris, pH 7.5 (TBS), 
resuspended in cell lysis buffer (150 mM NaCl, 10 mM 
Tris. 2 mM MgCl, pH 7.5) and incubated for 30 minutes 
at 0° C. according to usual practice. Infected cell nuclei 
containing non-enveloped virus are released from the 
cell and isolated by low speed centrifugation, washed 
twice in cell lysis buffer and subsequently lysed in nu 
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clei disruption buffer consisting of 5°72 sodium deoxy 
cholate in cell lysis buffer. The lysate is then incubated 
according to usual practice in the presence of 50 pg/ml 
DNase I (Sigma Chemical, St. Louis, Mo.) and clari?ed 
by low-speed centrifugation. The clari?ed supernatant 
is layered into a 5% to 45% glycerol step gradient. 
Nucleocapsids are pelleted by centrifugation and resus 
pended in TBS containing 10 mM ofthe protease inhibi 
tor phenylmethylsulfonyl ?ouride (Sigma Chemical, St. 
Louis, Mo.) Resuspended nucleocapsids are absorbed 
for 30 minutes at room temperature with Lens culinaris 
agglutinin covalently linked to agarose beads to remove 
any residual PR glycoproteins that may be present. The 
nucleocapsid preparation is aliquoted and stored at 
-70° C. until used. 
The proteins utilized in the assay of the present inven 
tion may also be prepared by recombinant DNA tech 
nology using the baculovirus expression system. Typi 
cally. a complementary DNA (cDNA) expression li 
brary is formed with lambda bacteriophage (gtll) which 
is screened with rabbit anti-nucleocapsid immunoglobu 
lin. The speci?c cDNA encoding each nucleocapsid 
protein is cloned into a baculovirus transfer vector 
which is used to insert the cDNA into the polyhedrin 
gene of the A utographic californica nuclear polyhedrosis 
virus. AfMNPv, resulting in the creation ofa recombi 
nant baculovirus. The speci?c nucleocapsid proteins 
can be produced in Spoa’optera frugiperda or any other 
suitable cells that are infected with recombinant virus 
resulting in the production of large quantities of the 
proteins. The recombinant nucleocapsid protein can be 
used in a standard immunoassay. such as the enzyme 
linked immunosorbant assay. for its ability to detect 
homologous antibody in virus infected subunit vacci 
nated and non-vaccinated pigs. 
More speci?cally, the production of recombinant PR 
virus nucleocapsid antigens using the baculovirus ex 
pression vector system can be accomplished in eight 
general steps: 
1. Identi?cation of immunogenic nucleocapsid anti 
gen candidates and generation of PR virus nucleocapsid 
speci?c monoclonal antibody and polyclonal hyperim 
mune serum. (23k, 34k, 41k, 63k and 140k relative mo 
lecular weights. 
2. Isolation of mRNA present in PR virus infected 
cells 6-9 hours post inoculation (period when the PR 
virus structural component genes, encoding enveloped 
glycoproteins and nucleocapsid proteins, are tran 
scribed) and synthesis of complementary DNA 
(cDNA) from these mRNA. 
3. Construction of a lambda bacteriophage (gtll) li 
brary using PR virus derived cDNA. 
4. Screening of clones obtained from step (3) using 
PR nucleocapsid speci?c hyperimmune serum to iden 
tify and isolate lambda gtll bacteriophage containing 
nucleocapsid genes. 
5. Excision of the putative nucleocapsid genes from 
gtll bacteriophage followed by ligation into specially 
designed baculovirus plasmid transfer vectors. 
6. Transfection of permissive insect cell culture with 
the transfer vector containing the putative nucleocapsid 
gene and infectious baculovirus DNA. 
7. Identi?cation and isolation of recombinant 
baculovirus expressing PR virus nucleocapsid genes 
using one or more of the following techniques: plaque 
phenotype, SDS-PAGE protein pro?le, antibody prob 
ing of plaques, or radioimmunoprecipitation of recom 
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binant baculovirus using nucleocapsid speci?c anti 
body. 
8. Expansion of con?rmed PR virus nucleocapsid/ 
baculovirus recombinants in insect tissue culture and 
isolation of nucleocapsid antigens either expressed and 
secreted or incorporated into the baculovirus. 
The PR virus nucleocapsid proteins of the present 
invention can be characterized by molecular weight 
determination. For example, the isolated non-enveloped 
PR virions can be electrophorectically separated to 
resolve individual nucleocapsid proteins under reduc 
ing conditions using standard SDS-PAGE methodol 
ogy according to B.D. Hames, Gel Electrophoresis of 
Proteins: A Practical Approach, Chapter 1, IRL Press, 
Washington, DC. (1985). Further, commercially pre 
pared molecular weight standard proteins from Sigma 
Chemical Co., St. Louis, Mo., are separated according 
the same methodology to allow molecular weight esti 
mates on individual PR virus nucleocapsid proteins. 
The resolved nucleocapsid proteins and molecular 
weight standards are‘ then electrophoretically trans 
ferred to nitrocellulose paper using the Western im 
munoblot assay. A manufacturer of Western immuno 
blot transfer apparatus is Bio-Rad, Inc., Richmond, 
Calif. 
Following separation and transfer, the molecular 
weight standards are cut from the nitrocellulose sheet 
and stained for total protein according to known proce 
dures. Hancock, et al., Anal. Biochem, 133:157-162 
(1983). Typically. the procedure allows the investigator 
to visualize and make migration measurements on indi 
vidual molecular weight standard proteins. The relative 
mobility (Rt) of the molecular weight standards and 
their reported molecular weights are used to construct 
a standard curve by best-?t line/linear regression analy 
sis. The standard curve is used to estimate the molecular 
weight of the nucleocapsid proteins using their respec 
tive Rf values on a standard curve generated as de 
scribed. FIG. 1 describes the values plotted on semi-log 
paper and the best-?t line is made. The proteins identi 
?ed for use in the present invention include those hav 
ing molecular weights of 140k, 63k, 41k, 34k and 23k. 
These proteins have been found to be effective in the 
present invention when used singly or in combination. 
The nucleocapsid proteins described above can be 
used in conventional standard immunoassay proce 
dures, for example-any assay where the swine serum 
and selected nucleocapoid antigen may be combined 
and prepared for a time and under conditions sufficient 
for formation of immune complexes between the anti 
body in the serum and the antigen and detecting the 
presence of immune complexes. Some of these assays 
include the competitive and indirect enzyme-linked 
immunosorbant assay (ELISA) procedure, described in 
van Oirshot, et al., J. Gen. Virol., 67:1179-1182 (1986) 
and McGinley and Platt, Am. J. Vet. Res, 49:1489-1493 
(1988), respectively; the immunoblot assay, described in 
McGinley and Platt, Am. J. Vet. Res. 1989, (accepted 
for publication) and in Towbin and Gordon, J. 
Immunol. Merit, 72:313-34-0 (1985); the agglutination 
assay using latex particles, described in Weiss?eld and 
Sonenworth, .l. Clin. Microbiol, l6:97l—972 (1982); the 
radial immunodiffusion enzyme assay, described in .100, 
et al., Am J. Vet. Res, 45:2096-3098 (1984); the radioim 
munoassay, described in Yalow, Textbook of Endocrinol 
ogy. ed. Williams, pp. 123-132, the indirect hemaggluti 
nation assay as described in Bernstein and Stewart, 
Appl. Microbiol, 21:84-89 (1971), the microimmunodif 
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fusion assay. described in Ouchterlony, Acra Pathol. 
.Microbiol. Scand. 25:186-191 (1948). and others. 
All of these assays include a step in which the se 
lected protein antigen is exposed to the serum sample 
for selective binding reaction with antibodies in the 
serum which have been generated to the same protein 
antigen. for example, by pseudorabies viral replication 
in the pig from which a serum specimen is obtained. 
The method of this invention and the preparation of 
the nucleocapsid proteins utilized therein is further 
illustrated by the following experimental examples: 
EXAMPLE 1 
PR Virus Nucleocapsid Antigen Preparation 
PR virus nucleocapsids were produced and isolated 
using a modi?cation ofthe method described by Gibson 
and Roizman for isolation of herpes simplex type I and 
11 by nucleocapsids. J. Virol., 10:1044-1052 (1972). Cell 
monolayers are prepared in plastic roller bottles. The 
cell type used is Madin Darby bovine kidney cells (Na 
tional Veterinary Services Laboratory, Ames, Iowa). 
Other cell types that support the replication of pseudo 
rabies virus may also be used. The cell monolayers are 
inoculated with pseudorabies virus strain Be (Platt. et 
al.. Arch Virol. 60:13-23 (1979)) at a multiplicity ofinfec 
tion of 5.0 and incubated at a temperature of 37° C. The 
cells were harvested 24 hours later with the aid of glass 
beads and pelleted by low speed centrifugation at 
1.000>< g for 15 minutes. The cell pellets were washed 
three times in 500 m NaCl, 20 mM Tris, pH 7.5 (TBS), 
resuspended in 20 ml of cell lysis (CL) buffer consisting 
of 150 mM NaCl, 10 mM Tris, 2 mM MgCl2, pH 7.5, 
containing 1% Nonidet P-40 and incubated for 30 min 
utes at 0" C. Infected cell nuclei were isolated by low 
speed centrifugation. washed twice in CL buffer and 
lysed in nuclei disruption buffer consisting of 5% so 
dium deoxycholate in CL buffer. The lysate was incu 
bated at 37° C. for one hour in the presence of 50 pg/ml 
DNase I and clari?ed by low speed centrifugation. The 
clari?ed supernatant was layered onto a 5% to 45% 
glycerol step gradient. Nucleocapsids were pelleted by 
centrifugation at 24,000 rpm for 90 minutes and resus 
pended in TBS containing 10mM of the protease inhibi 
tor phenylmethylsulfonyl ?uoride. Resuspended nu 
cleocapsids were adsorbed for 30 minutes at room tem 
perature with Lens culinaris agglutinin covalently 
linked to agarose beads to remove any residual PR virus 
glycoproteins that might be present. The nucleocapsid 
preparation was aliquoted and stored at —70° C. 50 
dium Dodecyl SulfaIe-Polyacnrlamide Gel Electrophoresis 
(SDS-PAGE). 
PR virus nucleocapsid protein and molecular weight 
markers were diluted in an'equal volume of sample 
preparation buffer consisting of 2% SDS, B-mercaptoe 
thanol, 0.05% bromophenol blue and 50% glycerol in 
0.5M Tris buffer, pH 6.8, boiled for 5 minutes and sepa 
rated under reducing conditions by standard SDS 
PAGE methods. Stacking and separating gels consisted 
of 4% and 10% acrylamide monomer respectively, 
cross-linked with bis-acrylamide at a ratio of 3010.8. All 
gels were electrophoresed at 25 mA until the samples 
reached the stacking gel/separating gel interface. Sam 
ple separation was completed by electrophoresis at a 
constant current of 35 mA until the dye front had mi 
grated 15 cm. The 15 cm migration limit was imposed 
on all separations in an attempt to standardize protein 
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migration patterns for later molecular weight determi 
nations and comparisons. 
Electrophoretic Transfer of PR Virus Proteins 
PR virus nucleocapsid protein and pre-stained molec 
ular weight standards were electrophoretically trans 
ferred to nitrocollulose membranes immediately follow 
ing SDS-PAGE. Proteins were transferred for 16 hours 
at 30 V followed by a two hour ?nishing period at 100 
V in transfer buffer consisting of 25 mM Tris, 192 mM 
glycine, pH 8.3 and 20% v/v methanol. Following 
transfer, the nitrocellulose membranes were cut into 0.5 
cm strips, air dried, and used immediately. The ef? 
ciency of transfer and total protein pro?le was evalu 
ated by india ink total protein staining. 
Western lmmunoblot Assay 
Nitrocellulose strips containing separated nucleocap 
sid protein were blocked with 2.5% gelatin in TBS for 
two hours at 37° C. and were washed for three S-minute 
cycles in TBS containing 0.05% Tween (20) TTBS). 
Positive control, negative control and sample sera were 
diluted 1/100 in TTBS containing 1% gelatin, incu 
bated with the nitrocelluose strips for one hour at room 
temperature, and washed as described above. Speci?c 
antigen-antibody reactions were visualized with biotin 
labeled goat anti-porcine lgG (H+L) secondary anti 
body diluted 1/2000 and streptavidin-horseradish per 
oxidase conjugate diluted 1/4-000. All incubations were 
for one hour at room temperature with washing as de 
scribed above. Enzyme substrate was prepared immedi 
ately before use and consisted of 60 mg of 4-chloro-1 
napthol in 20 ml of ice cold methanol and 60 pl] of cold 
30% hydrogen peroxide in 100 ml of TBS. Color reac 
tions were developed at room temperature in the dark 
for 40 minutes and stopped by two brief washes in de 
ionized water. Non-speci?c reactions were identi?ed by 
incubating nucleocapsid protein nitrocellulose strips 
with TTBS containing 1% gelatin in place of serum. 
The reported molecular weights represent a minimum 
of three ‘independent measurements. 
EXAMPLE 2 
PR Virus Subunit Vaccine Preparation 
The vaccine can be prepared by conventional means, 
such as that described by Platt, et al., Vet. MicrobioL, 
11:25-40 (1986). Essentially, viral glycoproteins were 
extracted from detergent solubilized PR virus infected 
porcine kidney 1a cells (Veterinary Medical Research 
Institute; Iowa State University, Ames, Iowa) isolated 
by lectin affinity chromatography using Lens culinarz's 
agglutinin covalently linked to agarose beads (E-Y Lab 
oratories, San Mateo, Calif). Bound glycoprotein was 
eluted with 2.5% mannose in 0.025M Tris/Tricine, pH 
8.4 and concentrated 10~fold by ultra~?1tration through 
a membrane (Amacon Corp, Danvers, Mass.) with a 
30,000 molecular weight cut'off limit. The protein con 
centration of the column eluate was determined by a 
dye binding method described by Bradford, Anal. Bio 
chem, 72:248-252 (1976). Vaccine antigen was diluted 
in Tris/Tricine and emulsi?ed in an equal volume of 
Freund‘s incomplete adjuvant. 
EXAMPLE 3 
Ten pigs were inoculated subcutaneously with one 
100 pg and two 50 pg doses of viral glycoprotein vac 
cine antigen, as described in Example 2, at three-week 
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intervals. Vaccinates and six nonwaccinated controls 
were nasally challenged with 103-3 PFU of PR virus in 
2 ml of maintenance medium. 21 days after the third 
vaccine dose. Serums were collected on days 0. 4. 7, l0. 
l4, and 21 post challenge and assayed for serum neutral 
ization and nucleocapsid speci?c antibody. The control 
pigs were terminated at this time. Challenged vacci 
nates were maintained through day 113 post-challenge 
and the antibody response of these pigs to individual 
nucleocapsid protein was characterized by the Western 
immunoblot assay. Speci?c antibody responses to indi 
vidual proteins are shown in Tables I and 11: 
TABLE I 
The collective antibody response of 10 subunit 
vaccinated pigs to nucleocapsid protein (NCP) 
as detected by Western immunoblot assay. 
Dav Tested Post-Challenge 
NCP 0 7 I0 14 21 32 53 96 113 
1401. 0” 0 0 8 8 8 7 6 4 
63k 0 0 0 9 9 9 7 5 5 
41k 0 0 0 l0 l0 l0 9 9 7 
34k 0 0 0 l0 l0 l0 8 6 6 
23k 0 0 0 8 8 B K 8 8 
‘Total number of pigs “llh detectable i?llbOd) to nucleocapod protein. 
TABLE I] 
The individual antibody response of 10 subunit 
vaccinated pigs to five nucleocapsid proteins 
(NCP) as detected by Western immunoblot 
assa\~ on day 113 post-challenge. 
Pig No. 140k 63k 41k 34k 23k 
I +0 w’ — b -t- "l" 
2 4 -v- + — - 
3 -— -— 1- — + 
4 _ _ _ _ __ 
5 — - + + + 
6 - - + + + 
7 + + '1- — -.> 
8 - - 4 -:- + 
9 + + + -.~ + 
I0 — .1. _ + + 
'71-) = NcP-spect?t anttbod) detected 
‘’t—) = NCP-spcct?c antibody not detected 
Subunit-vaccinated pigs became non-clinically in 
fected with PR virus following nasal challenge as indi 
cated by a four to eight fold increase in individual serum 
neutralization antibody titers to maximum levels which 
occurred at day 21 post-challenge. The serum neutral 
ization procedure is described by Platt. et al., Vet. Mi 
crobioL. 11:25-40 (1986). The serum neutralization titers 
of individual pigs steadily declined thereafter through 
day 113 post-challenge indicating that periods of viral 
recrudesence did not occur. Non-immunized control 
pigs survived virus challenge but became depressed, 
stopped eating, lost weight and developed respiratory 
congestion. These pigs were killed on day 21 post-chal 
lenge. 
A representative antibody response of subunit-vac 
cinated, 21 days post-challenge antibody response (B) 
and non-immunized control (A) pigs to nucleocapsid 
proteins as detected by the Western immunoblot assay 
following virus challenge was determined. Antibody to 
a total of eight proteins was detected. However, only 
?ve nucleocapsid proteins with molecular weights of 
140k. 63k, 41k, 34k and 23k were consistently detected 
with PR virus speci?c antibody. The three remaining 
nucleocapsid proteins with molecular weights of 120k, 
82k and 26k were not consistently detected with spe 
ci?c antibody. Two additional bands represented prote 
ins with molecular weights of 56k and 30k that consis 
15 
20 
25 
30 
35 
45 
50 
55 
65 
8 
tently reacted‘ non-speci?cally with the biotin/strep 
tavidin conjugate following incubation with buffer 
alone. 
In Table I. it is noted that no antibody to PR virus 
nucleocapsid proteins was detected in 10 immunized 
pigs prior to virus challenge. Antibody to each of the 
?ve nucleocapsid proteins was ?rst detected on day 14 
post-challenge in immunized and non-immunized pigs. 
The most immunogenic of the ?ve nucleocapsid prote 
ins were the 23k, 34k and 41k proteins based on the 
number of pigs that produced antibodies to these prote 
ins throughout the 113 day test period. Antibody to 
these three nucleocapsid proteins was initially detected 
in eight, ten and ten pigs, respectively, and continued to 
be detected through day 113 post-challenge in eight, six 
and seven pigs, respectively. See Tables I and II. 
EXAMPLE 4 
Indirect Enzyme-Linked Immunosorbant Assay 
(ELISA) 
Individual or combinations of nucleocapsid protein 
are used in the indirect enzyme-linked immunosorbant 
assay (ELISA) for the detection of PR virus speci?c 
antibodies. The test is performed by diluting nucleocap 
sid protein in antigen coating buffer consisting of 0.02 M 
sodium carbonate/bicarbonate buffer pH 9.6 containing 
1 mg/ml of water soluble carbodiimide l-ethyl-3-(-3 
dimethylaminopropyl) carbodiimide (Sigma Chemical 
Company, St. Louis, Mo.) to enhance antigen binding. 
One hundred pl of antigen preparation is incubated at 4" 
C. for 16-24 hours in individual wells of polystyrene 
microplates (lmmunlon I microplates, Dynatech Labs, 
Inc., Alexandria. Va.). Unadsorbed antigen is removed 
by washing all wells three times with 0.01M phosphate 
buffered saline. pH 7.2 containing 0.5% Tween 20 
(ELISA wash buffer). Unreacted sites are blocked by 
treating individual wells with 2.0% gelatin in antigen 
coating buffer for two hours at 37° C. Serums to be 
tested are diluted 1/20 in antibody/conjugate diluent 
consisting of 0.5M Tris, 150 mM sodium chloride, 0.01 
mM EDTA, pH 7.4 containing 0.5% Tween and 1.0% 
gelatin. Diluted serums are added at a rate of 100 pl to 
individual nucleocapsid protein coated wells and to 
control wells coated with 2% gelatin. Diluted serums 
are incubated at 37° C. for 15 minutes, washed eight 
times with ELISA wash buffer and air dried for 10 
minutes. Goat anti-porcine IgG (I~I+L) conjugated to 
horseradish perioxidase (Kirkegaard & Perry Laborato 
ries, lnc., Gaithersburg, Md.) is diluted 1/3500 in an 
tibody/conjugate diluent, added at a rate of 100 [,1] well 
and incubated at 37° C. for 45 minutes. Plates are 
washed eight times with ELISA wash buffer as de 
scribed above. One hundred p.l of enzyme substrate is 
prepared by adding 50 pl of a 30% concentrated solu 
tion of hydrogen peroxide and 20 mg of o 
phenylenediamine chromagen to 100 ml of 0.02M citric 
acid, pH 5.0, and added to individual wells and reacted 
in the dark at 25° C. for 20 minutes. The resulting color 
reactions are stabilized with 4.5M sulfuric acid. Absor 
bance values are determined with an automatic micro 
plate reader (Dynatech M11600 microplate reader, 
Dynatech Labs, Inc.) equipped with a test ?lter wave 
length of 490 nm. Absorbance values of individual sam 
ples are determined by subtracting the optical density 
value of control wells from the optical density value of 
nucleocapsid protein coated wells and expressed as the 
5,122,447 
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mean of four replications. A baseline optical density 
reaction is established with 40 known negative serums 
that give a corrected optical density range of 0.000 to 
0.050. Corrected optical density values of 0.150 or 
greater are considered positive. Mean corrected optical 
density values of 0.051 to 0.149 are considered suspi 
cious. Values equal to or less than 0.150 are considered 
negative. 
EXAMPLE 5 
Competitive Enzyme-Linked lmmunosorbant Assay 
(ELISA) 
Individual or combinations of nucleocapsid protein‘ 
are also used in the competitive ELISA. Individual 
wells of microtiter plates are coated with nucleocapsid 
protein and/or gelatin as described in Example 4. Alter 
natively, nucleocapsid protein can be bound to wells by 
antibody-antigen capture using nucleocapsid protein 
speci?c mouse monoclonal antibodies. Swine serums to 
be tested are diluted 1:20 in antibody/conjugate diluent. 
Diluted serums are added at a rate of 100 pl to individ 
ual nucleocapsid protein coated wells and gelatin 
coated control wells. Microtiter plates are incubated at 
37° C. for 45 minutes. washed eight times with ELISA 
wash buffer and air dried for 10 minutes. An optimum 
dilution of goat anti-nucleocapsid protein speci?c poly 
clonal or mouse monoclonal antibodies conjugated to 
horse radish perioxidase is added at a rate of 100 pl to 
individual test and control wells. Microtiter plates are 
incubated at 37° C. for 45 minutes and washed as above. 
Enzyme substrate is added to individual wells, color 
reactions are allowed to develop and are stabilized as 
described in Example 4. Absorbance values are deter 
mined as described in Example 4. Corrected optical 
density values of 0.150 an greater are negative. Values 
between 0.149 and 0.075 are suspicious and values less 
than 0.075 are considered positive. 
Pigs immunized with viral envelope protein and sub 
sequently exposed to a low dose of virus will produce 
detectable antibodies to at least ?ve nucleocapsid prote 
ins with molecular weights of 140k. 63k. 41k, 34k and 
23k. The 23k. 34 k and 41 k proteins were the most 
immuogenic based on the amount of time that speci?c 
antibodies could be detected in individual pigs. Further, 
nine of ten vaccinated pigs had detectable antibodies to 
one or more of these proteins at any time during the 113 
day test period. Consequently, these nucleocapsid pro 
teins are useful as a universal diagnostic antigen in indi 
rect and competitive enzyme-linked immunoassays. 
Upon reviewing the results of the Western immuno 
blot assay and the following examples, it may be argued 
that the assay was able to detect antibody to nucleocap 
sid protein following a low dose virus exposure because 
the pigs were sensitized with nucleocapsid protein that 
may have been present in the immunizing preparation. 
This possibility is considered unlikely because antibody 
to nucleocapsid protein was ?rst detected on day 14 
post-challenge in both immunized and non-immunized 
control pigs. Failure to detect antibody to nucleocapsid 
protein earlier in immunized pigs and in control pigs 
indicates that the presence of nucleocapsid protein spe 
ci?c antibody was a result of a primary immune re 
sponse. 
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EXAMPLE 6 
Dot Immuno~Blot Assay Using PrV Nucleocapsid 
Antigen 
The following example involves the detection of 
nucleocapsid speci?c antibody using a procedure simi 
lar to the indirect ELISA technique. The difference in 
this application is that antigen is bound to. and antibody 
reactions take place on a membrane solid support such 
as nitrocellulose. 
The following procedure requires that a vacuum 
?ltration apparatus be used. One such apparatus is the 
Bio-Dot micro?ltration apparatus (Bio-Rad Laborato 
ries). A nitrocellulose membrane cut to ?t the apparatus 
is thoroughly wetted in 20 mM Tris. 500 mM NaCl, pH 
7.5 (TBS). The wetted membrane and vacuum ?ltration 
apparatus are assembled as per manufacturer's instruc 
tions. One hundred pl of an antigen solution containing 
the nucleocapsid protein(s) diluted in TBS is added to 
all wells of the Bio-Dot apparatus and allowed to bind 
to the nitrocellulose by gravity ?ow (approximately 
3040 minutes). After the antigen solution has com 
pletely drained from the wells, 200 pl of blocking solu 
tion (TBS+0.05% Tween 20 and 2% gelatin) is added 
to all wells and allowed to gravity ?ow through the 
membrane (approximately 60 minutes). Following com 
pletion of blocking. 300 pl of TTBS wash solution 
(TBS-+0.05% Tween 20) is added to all wells and 
drawn through using a slight vacuum. This wash step is 
repeated a minimum of three times. 
A membrane prepared in the above manner can now 
be probed with serum from a pig immunized with a PrV 
envelope glycoprotein(s) subunit vaccine for reactivity 
with nucleocapsid antigen. The antibody probing 
would proceed as follows: sample pig sera would be 
diluted (typically 1:20 to 1:100) in antibody buffer 
(TTBS+ 1% gelatin) and 100 pl of each diluted sample 
applied to the appropriate sample well. The antibody 
solution (termed ?rst antibody) is allowed to react with 
the bound nucleocapsid antigen by gravity ?ltration 
(30-40 minutes). Following the ?rst antibody reaction, 
the membrane is washed three times (300 pl per wash) 
with TTBS as previously described. Following removal 
of excess wash solution by vacuum application, 100 pl 
of diluted (typically 1:1000 to 1:3000) goat anti-pig IgG 
conjugated with horseradish peroxidase (termed 2nd 
antibody-HR?) is added and allowed to react by grav 
ity ?ltration as previously described. The membrane is 
washed three times with TTBS as described above 
followed by three washes in TBS prior to color devel 
opment. 
The presence of speci?c anti-nucleocapsid antibody 
in the pig serum sample is now visualized by color de 
velopment of the nucleocapsid-1st antibody-2nd anti 
body-HRP complex that is bound to the membrane. 
Two hundred pl of color development solution (60 mg 
#chloro-l-napthol, 60 pl of cold 30% hydrogen perox 
ide, and 20 ml of cold methanol in 100 ml of TBS) is 
added to each well and allowed to react for 30 minutes 
at room temperature in the dark. The deposition of a 
purple precipitate (dot) indicates the presence of spe 
ci?c anti-nucleocapsid antibody. As in all assays of this 
type, appropriate known positive and known negative 
serum samples are included to gauge the reactivity of 
unknown serum samples. 
What is claimed is: 
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l. The method of testing serum from a swine vacci 
nated against pseudorabies virus with a viral pseudora 
bies envelope-based glycoprotein subunit vaccine to 
determine the presence of antibodies to infecting pseu 
dorabies virus. comprising performing an immunoassay 
on a swine serum specimen from said vaccinated animal 
by contacting the specimen with a protein reagent se 
lected from the group consisting of pseudorabies nu 
cleocapsid proteins having relative molecular weights 
of approximately 23kD, 34kD and 4lkD, or mixtures of 10 
said proteins, and determining is serum antibodies have 
bound to said protein reagent, antibody binding indicat 
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ing that the vaccinated animal has been infected by 
pseudorabies virus. 
2_ The method of claim 1 in which said protein rea 
gent is the pseudorabies nucleocapsid protein having a 
relative molecular weight of approximately 23kD. 
3. The method of claim 1 in which said protein rea 
gent is the pseudorabies nucleocapsid protein having a 
relative molecular weight of approximately 34kD. 
4. The method of claim 1 in which said protein rea 
gent is the pseudorabies nucleocapsid protein having a 
relative molecular weight of approximately 41kD. 
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